# Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

> **NCT00094835** · PHASE1,PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 51 (actual)

## Conditions studied

- Lung Cancer
- Non-Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Panitumumab
- **DRUG:** Motesanib diphosphate
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00094835
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2016-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00094835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00094835, "Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00094835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*